Icon times
Growth in US markets offset by de growth in other markets defined Q2 for Aurobindo Pharma | Q2 FY22 Result Analysis

Growth in US markets offset by de growth in other markets defined Q2 for Aurobindo Pharma | Q2 FY22 Result Analysis

Published on 16 November 2021 .Views 3 .Comments 0
Aurobindo Pharma’s revenue struggled as growth in US formulations has been offset by decline in topline for other markets. Also inflationary pressure due to which high raw material cost has led to a bleeding quarter for the company.

Please find attached for detailed analysis.
Attachments:
private article suscription area icon

You like to know more. We like that!

Please subscribe Model Portfolio Plan to get access of all premium model portfolio articles Only at Rs. 11,999.00/Year.

Please login to view this free article.

This blog is available only for logged in users, please register and get access to view this article.

Recently Uploaded


premium Premium
free Free
Chat on WhatsApp
Caret UP Arrow
InvestYadnya Support
Typically replies in minutes
InvestYadnya Support
Hi there
Welcome to InvestYadnya.
We are available to assist you on WhatsApp.
Please click on the button below to chat with us.
(10 AM to 7 PM IST)
16:10
Chat with InvestYadnya